The first U.S. Food and Drug Administration-approved oral medication for multiple sclerosis poses a potential risk of macular edema, particularly in patients with a history of uveitis, according to a neuro-ophthalmologist.
MS patients who receive Gilenya (fingolimod, Novartis) should undergo baseline and follow-up examinations 3 to 4 months after initiation of treatment, Robert C. Sergott, MD, said at the Wills Eye Institute Alumni Conference in Philadelphia.
“The macular edema issue is one that we as ophthalmologists are very familiar with and most neurologists are not familiar with,” he said. “It’s our obligation then to help them take care of these patients because we have an intersection of MS with a medication that can cause visual loss.”... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309
Users browsing this forum: No registered users